{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=19&q=castration-resistant", "query": { "q": "castration-resistant", "page": 19 }, "page_size": 10 }, "pagination": { "page": 19, "page_size": 10, "total_count": 768, "total_pages": 77, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=20&q=castration-resistant&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=18&q=castration-resistant&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T13:40:29.167Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02319837", "title": "Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hormone Sensitive Prostate Cancer", "Prostate Cancer", "Cancer of the Prostate" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Placebo (No longer applicable in Open Label study period)", "type": "DRUG" }, { "name": "Leuprolide Open Label", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1068, "start_date": "2014-12-17", "completion_date": "2027-07-30", "has_results": true, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-11-15T13:40:29.167Z", "location_count": 77, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 50 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02319837" }, { "nct_id": "NCT02903160", "title": "Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Radium-223 dichloride", "type": "DRUG" }, { "name": "cabazitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 40, "start_date": "2017-01-13", "completion_date": "2021-11-15", "has_results": true, "last_update_posted_date": "2024-02-07", "last_synced_at": "2026-11-15T13:40:29.167Z", "location_count": 2, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02903160" }, { "nct_id": "NCT01199146", "title": "Abiraterone Post Ketoconazole for Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Abiraterone acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 42, "start_date": "2010-09-10", "completion_date": "2016-03-14", "has_results": true, "last_update_posted_date": "2018-01-08", "last_synced_at": "2026-11-15T13:40:29.167Z", "location_count": 2, "location_summary": "San Francisco, California • Chicago, Illinois", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01199146" }, { "nct_id": "NCT04028388", "title": "ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer Metastatic", "Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Docetaxel in Parenteral Dosage Form", "type": "DRUG" }, { "name": "ModraDoc006/r", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Modra Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 135, "start_date": "2019-07-17", "completion_date": "2021-11-29", "has_results": true, "last_update_posted_date": "2024-04-17", "last_synced_at": "2026-11-15T13:40:29.167Z", "location_count": 4, "location_summary": "Detroit, Michigan • Las Vegas, Nevada • Portland, Oregon + 1 more", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Portland", "state": "Oregon" }, { "city": "Myrtle Beach", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04028388" }, { "nct_id": "NCT02384382", "title": "A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Carcinoma Metastatic to the Bone", "Castration Resistant Prostate Cancer" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 23, "start_date": "2015-11-30", "completion_date": "2019-05-03", "has_results": true, "last_update_posted_date": "2020-05-05", "last_synced_at": "2026-11-15T13:40:29.167Z", "location_count": 5, "location_summary": "Detroit, Michigan • Farmington Hills, Michigan • New Brunswick, New Jersey + 1 more", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Farmington Hills", "state": "Michigan" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Madison", "state": "Wisconsin" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02384382" }, { "nct_id": "NCT01576172", "title": "Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration-Resistant Prostate Carcinoma", "Recurrent Prostate Carcinoma", "Stage IV Prostate Cancer AJCC v7" ], "interventions": [ { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Veliparib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 159, "start_date": "2012-03-30", "completion_date": "2020-04-23", "has_results": true, "last_update_posted_date": "2020-11-12", "last_synced_at": "2026-11-15T13:40:29.167Z", "location_count": 14, "location_summary": "Duarte, California • Los Angeles, California • South Pasadena, California + 10 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "South Pasadena", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01576172" }, { "nct_id": "NCT05398302", "title": "Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Castration-Resistant Prostate Carcinoma", "Metastatic Prostate Carcinoma", "Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8", "Stage IVA Prostate Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Image Guided Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 30, "start_date": "2024-04-26", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-11-15T13:40:29.167Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05398302" }, { "nct_id": "NCT02985957", "title": "A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Cabazitaxel", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 351, "start_date": "2017-03-26", "completion_date": "2025-01-07", "has_results": true, "last_update_posted_date": "2025-12-22", "last_synced_at": "2026-11-15T13:40:29.167Z", "location_count": 15, "location_summary": "Tucson, Arizona • Marietta, Georgia • Chicago, Illinois + 12 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02985957" }, { "nct_id": "NCT07677267", "title": "A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Prostatic Neoplasms, Castration-Resistant" ], "interventions": [], "intervention_types": [], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "115 Years", "sex": "MALE", "summary": "18 Years to 115 Years · Male only" }, "enrollment_count": 1067, "start_date": "2026-06-30", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-11-15T13:40:29.167Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07677267" }, { "nct_id": "NCT01560923", "title": "Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Prostate Cancer" ], "interventions": [ { "name": "Indoximod", "type": "BIOLOGICAL" }, { "name": "Sipuleucel-T", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 47, "start_date": "2012-10-01", "completion_date": "2018-12-12", "has_results": true, "last_update_posted_date": "2020-04-03", "last_synced_at": "2026-11-15T13:40:29.167Z", "location_count": 4, "location_summary": "Chicago, Illinois • Minneapolis, Minnesota • New York, New York + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01560923" } ] }